EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SNP genotypes in CYP2C9 and VKORC1 genes do not affect prostate cancer or cancer mortality among warfarin users in Finnish prostate cancer patients

Teemu J Murtola iD, Kaisa M Skantsi, Aino Siltari, Kirsi Talala, Kimmo Taari, Teuvo L J Tammela, Johanna Schleutker, Anssi Auvinen, Csilla Sipeky

PLOS One · 2025

DOI: 10.1371/journal.pone.0329438 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Teemu J Murtola und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. Hauptthemen laut MEDLINE: Warfarin, Polymorphism, Single Nucleotide, Vitamin K Epoxide Reductases, Cytochrome P-450 CYP2C9. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Finland, Cancer Foundation Finland sr, and Expert Responsibility Area of the Pirkanmaa Hospital District, Cancer Foundation Finland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The coagulation cascade is thought to contribute to cancer progression. Although in vitro studies suggest that anticoagulants, such as warfarin, might reduce cancer progression, epidemiological data indicate that warfarin users may have a higher risk of cancer mortality. However, single nucleotide polymorphisms (SNPs) that influence warfarin dosing might affect this association. We investigated the risk associations between warfarin use and prostate cancer (PCa) survival, considering the SNP genotypes of CYP2C9 and VKORC1 , which are known to impact both warfarin pharmacokinetics and pharmacodynamics, resulting in lower warfarin dose requirement. We genotyped 2,246 Finnish men with PCa from two different cohorts for SNPs rs1057910, rs1799853, and rs9923231. Genotyping was done using a custom Illumina iSelect genotyping array (iCOGs). Using Cox regression models, we calculated hazard ratios (HRs) and 95% confidence intervals (CI) for the risk of overall death, cancer deaths overall, and PCa-specific death after PCa diagnosis based on SNP genotypes. Data on warfarin purchases was obtained from a national registry. Our findings revealed that the SNPs did not alter the risk of cancer or PCa death in either cohort, nor did they modify the risk among warfarin users. However, overall mortality was higher among warfarin users compared to non-users, particularly in carriers of all three SNPs. Even though the increased mortality is likely due to confounding by indication, warfarin use may increase overall mortality especially in men with lower warfarin dose requirements due to SNP carrier status. However, we need further studies with larger populations to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WarfarinPolymorphism, Single NucleotideVitamin K Epoxide ReductasesCytochrome P-450 CYP2C9Prostatic NeoplasmsAnticoagulantsHumansMaleFinlandAgedGenotypeMiddle Aged

Substanzen

WarfarinVitamin K Epoxide ReductasesCytochrome P-450 CYP2C9VKORC1 protein, humanCYP2C9 protein, humanAnticoagulants

Autor:innen und Institutionen

  • Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • TAYS Cancer Center, Department of Urology, Tampere, Finland.
  • Department of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Finnish Cancer Registry, Cancer Society of Finland, Helsinki, Finland.
  • Department of Urology, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Institute of Biomedicine, University of Turku, Turku, Finland.

ORCID-Profile: Teemu J Murtola

Förderung

  • Academy of Finland
  • Cancer Foundation Finland sr, and Expert Responsibility Area of the Pirkanmaa Hospital District
  • Cancer Foundation Finland

Zitieren

APA

Murtola, T. J., Skantsi, K. M., Siltari, A., Talala, K., Taari, K., Tammela, T. L. J., Schleutker, J., Auvinen, A., & Sipeky, C. (2025). SNP genotypes in CYP2C9 and VKORC1 genes do not affect prostate cancer or cancer mortality among warfarin users in Finnish prostate cancer patients. PLOS One. https://doi.org/10.1371/journal.pone.0329438

Vancouver

Murtola TJ, Skantsi KM, Siltari A, Talala K, Taari K, Tammela TLJ, et al. SNP genotypes in CYP2C9 and VKORC1 genes do not affect prostate cancer or cancer mortality among warfarin users in Finnish prostate cancer patients. PLOS One. 2025. doi:10.1371/journal.pone.0329438

BibTeX
@article{Murtola2025,
  author = {Murtola, Teemu J and Skantsi, Kaisa M and Siltari, Aino and Talala, Kirsi and Taari, Kimmo and Tammela, Teuvo L J and Schleutker, Johanna and Auvinen, Anssi and Sipeky, Csilla},
  title = {SNP genotypes in CYP2C9 and VKORC1 genes do not affect prostate cancer or cancer mortality among warfarin users in Finnish prostate cancer patients},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0329438}
}
Kostenlos starten →